Annual revenue went from KRW 10.8 billion in 2022 to KRW 9.02 billion in 2023 (down 16.1% year on year), KRW 8.37 billion in 2024 (down 7.2%) and KRW 3.98 billion in 2025 (down 52.4%), declining for three consecutive years from 2023 to 2025. Among 2022 to 2025, 2022 was the largest year and 2025 the smallest.
The operating margin fell from 22.5% in 2022 to 11.4% in 2023 and 3.4% in 2024, and reached -103.0% in 2025. The 2025 operating loss of KRW 4.11 billion marked a swing from profit to loss.
Profit attributable to controlling shareholders fell from KRW 2.83 billion in 2022 to KRW 1.43 billion in 2023 (down 49.3%) and KRW 336 million in 2024 (down 76.6%), before turning into a net loss of KRW 4.9 billion in 2025.
Net income including non-controlling interests showed the same direction, with a net loss of KRW 4.9 billion in 2025. The direct trigger for the revenue collapse was the operating suspension of pharmaceutical quality testing in June 2025, which Dailypharm reported at KRW 5.9 billion, or 70.7% of revenue.
Quarterly revenue was KRW 296 million in Q3 2025, KRW 341 million in Q4 2025 (up 15.3% quarter on quarter), KRW 958 million in Q1 2026 (up 180.8%), KRW 1.29 billion in Q2 2026 (up 35.2%) and KRW 1.66 billion in Q3 2026 (up 27.8%), rising for four consecutive quarters from Q4 2025 to Q3 2026.
Operating losses narrowed from KRW 1.8 billion in Q3 2025 to KRW 811 million in Q3 2026 but have continued for five consecutive quarters. Profit attributable to controlling shareholders was a loss of KRW 973 million in Q2 2026, wider than the KRW 939 million loss in Q1 2026.
The loss attributable to controlling shareholders over the latest four quarters totaled KRW 4.38 billion. Operating cash flow declined from KRW 4.03 billion in 2022 to -KRW 2.19 billion in 2025, and equity stood at KRW 7.64 billion at the end of 2025 against total liabilities of KRW 3.59 billion.